A single-cell meta-analysis evidences transposable element dysregulation in sex-based differences in Parkinson's disease.

Neurobiol DisAug 30, 2026 (epub)
Clinical ResearchMedical GeneticsNeurology

Fernando Gordillo-González, Cristina Galiana-Roselló, Rubén Grillo-Risco et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined transposable element (TE) expression in Parkinson's disease (PD) using single-nucleus RNA-seq data from 66 donors. It revealed widespread TE activation in various brain cell types, with distinct male- and female-biased TE signatures. Notably, L1s were upregulated in neurons and HERVs in oligodendrocytes, suggesting sex-specific regulatory impacts on PD pathology.

Key findings

  • Widespread TE activation was observed across major brain cell types in PD.
  • L1s were significantly upregulated in neurons, while HERVs were upregulated in oligodendrocytes.
  • Distinct male- and female-biased TE signatures were identified, indicating sex-specific regulatory programs.
  • TE-gene associations linked to neuroinflammation and myelination pathways were uncovered.

Why it matters

Understanding the role of transposable elements in Parkinson's disease may provide insights into sex-specific mechanisms of the disease, potentially guiding future research and therapeutic strategies.

Source

PubMed · PMID 42669364

Published in Neurobiol Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Medical Genetics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.